Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers
Open accessAbstract
Prioritizing Ontario’s long-term care home (LTCH) residents for vaccination against severe acute respiratory syndrome coronavirus 2 has drastically reduced their disease burden; however, recent LTCH outbreaks of variants of concern (VOCs) have raised questions regarding their immune responses. In 198 residents, mRNA vaccine dose 1 elicited partial spike and receptor binding domain antibody responses, while the second elicited a response at least equivalent to convalescent individuals in most residents. Residents administered mRNA-1273 (Moderna) mounted stronger total and neutralizing antibody responses than those administered BNT162b2 (Pfizer-BioNTech). Two to four weeks after dose 2, residents ( n = 119, median age 88) produced 4.8–6.3-fold fewer neutralizing antibodies than staff ( n = 78; median age 47) against wild-type (with D614G) pseudotyped lentivirus, and residents administered BNT162b2 produced 3.89-fold fewer neutralizing antibodies than those who received mRNA-1273. These effects were exacerbated upon serum challenge with pseudotyped VOC spike, with up to 7.94-fold reductions in B.1.351 (Beta) neutralization. Cumulatively, weaker vaccine stimulation, age/comorbidities, and the VOC produced an ∼130-fold reduction in apparent neutralization titers in LTCH residents and 37.9% of BNT162b2-vaccinated residents had undetectable neutralizing antibodies to B.1.351. Continued immune response surveillance and additional vaccine doses may be required in this population with known vulnerabilities.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PTX-COVID19-B induced high titers of neutralizing antibodies against wild-type SARS-CoV-2 and variants Alpha, Beta, and Delta, comparable to those elicited by approved COVID-19 mRNA vaccines when assessed by the same neutralization assay.
“PTX-COVID19-B was shown to induce high titers of neutralizing antibodies against wild-type SARS-CoV-2 and variants, including Alpha, Beta, and Delta, which were comparable to those elicited by the approved COVID-19 mRNA vaccines when assessed by the same neutralization assay.431,432”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [431]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 37 · Cited by 32
Research works printed but not linked: 1
- Sheikh-Mohamed, S., et al., A mucosal antibody response is induced by intra-muscular SARS-CoV- 2 mRNA vaccination. medRxiv, 2021: p. 2021.08.01.21261297.
- Authors
- Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., Pasculescu, A., Fazel-Zarandi, M., Li, A., Paterson, A., Chao, G., Green, K., Gilbert, L., Barati, S., Haq, N., Takaoka, A., Takaoka, J. G., De Launay, K. Q., Fahim, C., Sheikh-Mohamed, S., Arita, Y., Durocher, Y., Marcusson, E. G., Gommerman, J. L., Ostrowski, M., Colwill, K., Straus, S. E., Wood, H., McGeer, A. J., & Gingras, A.-C.
- Affiliations
- Mount Sinai Hospital (CA)
- Public Health Agency of Canada (CA)
- University of Toronto (CA)
- St. Michael's Hospital (CA)
- National Research Council Canada (CA)
- Corresponding author
- McGeer, Allison J.
- Gingras, Anne-Claude
- ORCID
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2021-08-08
- OpenAlex
- W3191969853
- Cited by
- 32
- References
- 37
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 17 · 2021: 7
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Federal Open Science Repository of Canada / Le Dépôt fédéral de science ouverte du Canada (submittedVersion, cc-by-nc-nd)
- Funders
- Genome Canada (OGI-139)
- Public Health Agency of Canada
- Royal Bank of Canada
- Ontario Genomics (OGI‐139)
- Government of Ontario (OGI-139)
- Public Health Agency
- Canada Research Chairs (Tier1)
- Krembil Foundation
- Canadian Institutes of Health Research (COVID-19, VR-1 172 711, 439999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- SARS-CoV-2, long-term care facilities, neutralizing antibodies, mRNA-1273, BNT162b2, COVID-19 vaccination, variants of concern, Beta variant, vaccine response, long-term care workers, older adults
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
